Compare
Arexvy vs. Abrysvo

Arexvy (RSV vaccine) is the first FDA-approved vaccine to help lower your risk of getting serious lung infections caused by respiratory syncytial virus (RSV). You can get it if you're age 60 or older, and in some cases starting at age 18 if you have a higher risk of severe illness from RSV. Arexvy (RSV vaccine) is given once as a single injection into the muscle. Common side effects include tiredness, muscle pain, and injection site reactions like pain, swelling, or redness.

Prevention of serious lung infections caused by respiratory syncytial virus (RSV) in:

• Adults 60 years and older
• Adults 18 to 59 years old who have a higher risk of illness due to RSV

18 to 49 years old:

• Pain at the injection site (76%)
• Muscle pain (60%)
• Tiredness (60%)
• Headache (44%)
• Joint pain (28%)

50 to 59 years old:

• Pain at the injection site (76%)
• Tiredness (40%)
• Muscle pain (36%)
• Headache (32%)
• Joint pain (23%)

60 years and older:

• Pain at the injection site (61%)
• Tiredness (34%)
• Muscle pain (29%)
• Headache (27%)
• Joint pain (18%)

• Guillain-Barré syndrome
• Severe allergic reaction
• Fainting
• Weaker vaccine protection

Abrysvo (RSV vaccine) is a vaccine that helps lower your risk of getting serious lung infections caused by respiratory syncytial virus (RSV). It's FDA approved for adults 60 years and older, and adults 18 to 59 years who have a higher risk of getting seriously ill from RSV. It's also approved for pregnant mothers between 32 and 36 weeks gestation to help protect their babies from RSV after birth. Abrysvo (RSV vaccine) is given as a single injection into the muscle. Common side effects include tiredness, headache, and injection site reactions like pain, swelling, or redness.

Prevention of serious lung infections caused by respiratory syncytial virus (RSV) in:

• Adults 60 years and older
• Adults 18 to 59 years old who have a higher risk of illness due to RSV
• Pregnant mothers between 32 to 36 weeks gestation

18 to 59 years old:

• Tiredness (37%)
• Pain at injection site (35%)
• Headache (28%)
• Muscle pain (24%)
• Diarrhea (15%)
• Joint pain (12%)
• Nausea (12%)

60 years and older:

• Tiredness (16%)
• Headache (13%)
• Pain at injection site (11%)
• Muscle pain (10%)

Pregnant mothers:

• Tiredness (46%)
• Pain at injection site (41%)
• Headache (31%)
• Muscle pain (27%)
• Nausea (20%)

• Guillain‑Barré syndrome
• Potential risk of preterm (early) birth
• Severe allergic reaction
• Fainting
• Weaker vaccine protection